The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving FMT vs 61.2% of 49 patients receiving vancomycin. HealthDay News — ...
BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...
First-line treatment selection in follicular lymphoma is closely tied to tumor stage, disease burden, and patient-specific factors. Early-stage presentations may be managed with localized modalities, ...
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database Between April 2019 ...
Asbestos-associated latency necessitates careful exposure history, and symptom patterns differ between pleural and peritoneal disease, often reflecting effusion or serosal thickening. Tissue ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results